Tranexamic Acid is an acid compound whose pharmaceutical applications span formulation excipient use, synthetic reagent functions, and in some cases direct therapeutic activity. The pKₐ of Tranexamic Acid determines the ionisation equilibrium relevant to its GI absorption, renal clearance, and tissue distribution when present as an impurity or excipient component at trace levels. Occupational exposure to Tranexamic Acid in manufacturing environments is primarily assessed for irritant corrosive effects on the respiratory tract and skin, with OEL values reflecting the concentration producing no adverse local tissue effects in the most sensitive exposure studies.
The intraspecies uncertainty factor F2 for Tranexamic Acid covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients wi
